Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50–59 Years

(See the Editorial Commentary by Li et al, on pages 929–30.) Background. Herpes zoster (HZ) adversely affects individuals aged 50–59, but vaccine efficacy has not been assessed in this population. This study was designed to determine the efficacy, safety, and tolerability of zoster vaccine for preve...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Infect Dis
Main Authors: Schmader, Kenneth E., Levin, Myron J., Gnann, John W., McNeil, Shelly A., Vesikari, Timo, Betts, Robert F., Keay, Susan, Stek, Jon E., Bundick, Nickoya D., Su, Shu-Chih, Zhao, Yanli, Li, Xiaoming, Chan, Ivan S. F., Annunziato, Paula W., Parrino, Janie
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2012
Assuntos:
Articles and Commentaries
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4542655/
https://ncbi.nlm.nih.gov/pubmed/22291101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/cir970
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares